Hopec Pharma Overview
Hopec Pharma is transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) with HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy invented by Prof. Gilad Bachrach, Prof. Chamutal Gur, Prof. Ofer Mandelboim, and Dr. Vladimir Yutkin from the Hebrew University of Jerusalem and Hadassah Medical Center. This genetically modified Uropathogenic E. coli triggers a targeted immune response, offering higher efficacy, fewer side effects, and a scalable, cost-effective alternative to current treatment with Bacillus Calmette-Guérin (BCG). Founded in 2023 by Estee Rosen and Gadi Klarsfeld, Hopec Pharma leverages over 60 years of combined leadership in healthcare and pharma. The core team Dr. Ilan Winkler (VP Drug Development), Shoshi Friedman (VP Clinical Development), and Yohai Avrahami (Head of QA) brings extensive experience and execution strength within Israel’s biotech and clinical ecosystem. Hopec collaborates with leading Israeli partners: RS Ness serving as both CRO and regulatory affairs partner, Scinai Immunotherapeutics for GMP drug manufacturing, and BIFORUM for data management. In 2025, the company achieved major milestones: • Produced its first GMP clinical batch (DOR-100) • Received Helsinki approval (July 2025) for Phase 1/a+b • Signed clinical agreements with Hadassah and Sheba Medical Centers • Launched clinical trials (September 2025) • Awarded a grant from the Israel Innovation Authority (October 2025) Following strong preclinical results, Hopec entered human trials to validate HOPEC’s superior efficacy and safety. The company holds an exclusive IP license from Yissum and Hadasit with patents granted in the U.S., Europe, and China. With the NMIBC market projected to reach $8.6 billion by 2032, Hopec Pharma is well-positioned to lead the next generation of accessible, effective cancer immunotherapies that bring new hope and improve patients’ quality of life worldwide.
Cumulative Funding Raised Over Time ($)
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4M |
| Last funding | $3M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 0 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.hopec-pharma.com |
Locations
Ha-Te'ena St 1, Giv'at Shmuel, Israel
Photos & Videos
1 item(s)
Hopec Pharma Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsMicroorganismsTags (15)
drug-developmentclinical-trialstargeted-cancer-therapycancercancer-therapyoncologycancer-researchbiopharmaceuticalimmuno-theraphyhealthcarepharmaceuticalsbiotechnologylife-sciencesimmunotherapybacteriaGeographic Markets
ChinaNorth AmericaWestern EuropeHopec Pharma Financials
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Hopec Pharma Lifecycle
Cumulative Funding Raised Over Time
All Events
Hopec Pharma News
0 articlesNo news articles.
Hopec Pharma Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Hopec Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 80/100 |
| Missing | sector, news, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516759495 |
| Phone | 0547278898|0543080100 |
| Creator | Gadi Klarsfeld |
| Creator email | gadi@hopec-pharma.com |
| Last update | 2024-01-01T00:00:00.000Z |
| Created | 2024-01-01T00:00:00.000Z |
| Claimed | Yes |